Paper39600110
Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy.
Colombo G and 7 others. ESC Heart Fail, 2025. Cited by 16 papers, by iCite.
Cite this record
ConductScience Library. Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy. Papers, record 39600110. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39600110
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Heart Failure | Major topic |
| Ventricular Remodeling | Major topic |
| Stroke Volume | Major topic |
| Humans | |
| Mineralocorticoid Receptor Antagonists | |
| Angiotensin-Converting Enzyme Inhibitors | |
| Angiotensin Receptor Antagonists | |
| Adrenergic beta-Antagonists |
Source PubMed
References141
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33404637 | Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial. | JAMA Cardiol | 2021 | https://conductscience.org/library/papers/33404637 | PubMed |
| 2 | 31707802 | Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan. | Circ Heart Fail | 2019 | https://conductscience.org/library/papers/31707802 | PubMed |
| 3 | 33129742 | Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure: A Multimodality Study. | JACC Cardiovasc Imaging | 2021 | https://conductscience.org/library/papers/33129742 | PubMed |
| 4 | 32558989 | Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. | Eur J Heart Fail | 2020 | https://conductscience.org/library/papers/32558989 | PubMed |
| 5 | 33766629 | Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials. | Pharmacol Res | 2021 | https://conductscience.org/library/papers/33766629 | PubMed |
| 6 | 15949473 | Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction. | Cardiovasc Res | 2005 | https://conductscience.org/library/papers/15949473 | PubMed |
| 7 | 35334137 | Cardiac remodelling - Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. | Eur J Heart Fail | 2022 | https://conductscience.org/library/papers/35334137 | PubMed |
| 8 | 32415802 | The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA-HF study. | Diabetes Metab Res Rev | 2020 | https://conductscience.org/library/papers/32415802 | PubMed |
| 9 | 39600110 | Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy. | ESC Heart Fail | 2025 | https://conductscience.org/library/papers/39600110 | PubMed |
| 10 | 15201244 | Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study. | Heart | 2004 | https://conductscience.org/library/papers/15201244 | PubMed |
| 11 | 30586756 | Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation. | Circulation | 2019 | https://conductscience.org/library/papers/30586756 | PubMed |
| 12 | 36183276 | Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study. | Circulation | 2022 | https://conductscience.org/library/papers/36183276 | PubMed |
| 13 | 31768479 | Atrial Myopathy. | JACC Basic Transl Sci | 2019 | https://conductscience.org/library/papers/31768479 | PubMed |
| 14 | 29806165 | Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. | Eur J Heart Fail | 2018 | https://conductscience.org/library/papers/29806165 | PubMed |
| 15 | 22157723 | Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. | Circ Heart Fail | 2012 | https://conductscience.org/library/papers/22157723 | PubMed |
| 16 | 8941106 | Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. | Circulation | 1996 | https://conductscience.org/library/papers/8941106 | PubMed |
| 17 | 33669786 | Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/33669786 | PubMed |
| 18 | 7963115 | Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. | J Am Coll Cardiol | 1994 | https://conductscience.org/library/papers/7963115 | PubMed |
| 19 | 33189632 | Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. | JACC Heart Fail | 2021 | https://conductscience.org/library/papers/33189632 | PubMed |
| 20 | 16141258 | Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. | Eur Heart J | 2005 | https://conductscience.org/library/papers/16141258 | PubMed |
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42985589 | Exploration of the Pathogenesis and Treatment of Heart Failure. | Rev Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42985589 | PubMed |
| 42888505 | Prognostic impact of moderate secondary mitral regurgitation after optimized medical therapy in heart failure. | ESC Heart Fail | 2026 | https://conductscience.org/library/papers/42888505 | PubMed |
| 42781099 | Disulfidptosis in heart failure: an emerging mechanism awaiting exploration. | Front Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42781099 | PubMed |
| 42679352 | Dapagliflozin effects on right ventricular function, pulmonary pressure and coupling: a propensity score analysis from the RIVED-HF. | ESC Heart Fail | 2026 | https://conductscience.org/library/papers/42679352 | PubMed |
| 42315195 | Cardioprotective role of antihypertensive treatment in chemotherapy-induced cardiotoxicity: umbrella review of meta-analyses of randomised controlled trials. | Open Heart | 2026 | https://conductscience.org/library/papers/42315195 | PubMed |
| 42283978 | Probing Early Myocardial Remodeling in Response to a High-Fat Diet in Mice by Evaluation of Extracellular Volume Fraction Using 4D Retrospectively Gated Micro-CT Imaging. | Mol Imaging Biol | 2026 | https://conductscience.org/library/papers/42283978 | PubMed |
| 42161423 | Cardiac MRI in cardiac dystrophinopathy: recommendations on imaging. | Open Heart | 2026 | https://conductscience.org/library/papers/42161423 | PubMed |
| 41995966 | Targeting the Apelin-APJ Axis: A Promising Strategy to Mitigate Anthracycline-Induced Cardiotoxicity. | Cardiovasc Toxicol | 2026 | https://conductscience.org/library/papers/41995966 | PubMed |
| 41329532 | Effects of Isovolumic Loading Elicited Either by 3-Branch or by 4-Branch Spring Expander on the Degree of Cardiac Atrophy of the Failing Heart in Rats After Heterotopic Heart Transplantation: No Evidence for Sex-Linked Differences. | Physiol Res | 2025 | https://conductscience.org/library/papers/41329532 | PubMed |
| 41303740 | SGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: A New Therapeutic Era. | Medicina (Kaunas) | 2025 | https://conductscience.org/library/papers/41303740 | PubMed |
| 41155138 | Cardioprotective Mechanisms of Beta-Blockers in Myocardial Ischemia and Reperfusion: From Molecular Targets to Clinical Implications. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41155138 | PubMed |
| 41089789 | New Fuels for a Failing Engine: The Impact of Novel Heart Failure Drugs on Functional Capacity. | Rev Cardiovasc Med | 2025 | https://conductscience.org/library/papers/41089789 | PubMed |
| 40841934 | Beta-Blockers and mortality in patients with malignancy and cardiovascular disease: an analysis of the MIMIC-IV database. | BMC Cancer | 2025 | https://conductscience.org/library/papers/40841934 | PubMed |
| 40672521 | Regulatory Effects of Zhenxin Formula in Treating Doxorubicin-Induced Heart Failure: Network Pharmacology and Animal Experimental Verification. | Drug Des Devel Ther | 2025 | https://conductscience.org/library/papers/40672521 | PubMed |
| 40629225 | Gut microbiota's role in heart failure. | Heart Fail Rev | 2025 | https://conductscience.org/library/papers/40629225 | PubMed |
| 40142759 | Eligibility of Outpatients with Chronic Heart Failure for Vericiguat and Omecamtiv Mecarbil: From Clinical Trials to the Real-World Practice. | J Clin Med | 2025 | https://conductscience.org/library/papers/40142759 | PubMed |
| 39600110 | Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy. | ESC Heart Fail | 2025 | https://conductscience.org/library/papers/39600110 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39600110
GET https://conductscience.org/api/papers/v1/39600110/references?page=2